Eko Health

High-Level Overview

Eko Health is a pioneering AI-powered digital health company that builds advanced digital stethoscopes, ECG devices, software platforms, and AI analysis tools to enable earlier detection and monitoring of heart and lung diseases.[1][5][6] It serves over 600,000 healthcare providers worldwide, including clinicians in hospitals, clinics, virtual care settings, and health systems operating 800+ US hospitals, solving the problem of inaccurate or missed diagnoses in noisy environments or remote exams by delivering high-fidelity audio, real-time ECG visualization, and FDA-cleared AI flagging murmurs, atrial fibrillation (AFib), low ejection fraction, and more in as little as 15 seconds.[1][4][6] With over 650,000 devices sold globally—the largest connected digital stethoscope network—Eko drives growth through telehealth integrations, life sciences partnerships for data generation, and expansions like its UK launch, enhancing virtual cardiac/pulmonary exams and scaling detection across physical and remote care.[1][2][4]

Origin Story

Eko Health, headquartered in Emeryville, California, emerged as a commercial-stage cardiac health technology company focused on reinventing the stethoscope into an AI-enabled early disease detection platform, akin to how Ring transformed doorbells into security systems.[1][7] Co-founder and CEO Connor Landgraf leads the team, backed by investors like Questa Capital, with key executives including Co-founder and Chief Business Officer Jason Bellet, who has highlighted Eko Telehealth's role in virtual care.[1][7] The idea stemmed from proprietary cardiac detection algorithms powering connected devices, gaining early traction through FDA clearances (9 total for devices and AI), partnerships like Mayo Clinic (50+ publications), and massive device adoption, evolving from core auscultation tools to a full ecosystem including telehealth streaming and bioPharma data solutions.[6][7]

Core Differentiators

• FDA-Cleared AI Integration: Processes heart/lung sounds and ECG data in real-time, flagging key indicators (murmurs, AFib, low EF) with high accuracy—e.g., 99% sensitivity/97% specificity for AFib, 85%/70% for low EF—backed by millions of heart sounds and 2x better disease detection than analog stethoscopes.[6]
• Superior Audio and Visualization: Active noise cancellation, 8x sound improvement, three listening modes (wide, cardiac, pulmonary), and simultaneous phonocardiogram/ECG waveforms for precise exams in any setting.[1][3][4]
• Telehealth and Remote Capabilities: Eko Telehealth streams high-fidelity data into virtual workflows (hospital-at-home, virtual nursing), compatible with 650,000+ devices, bridging physical-remote gaps without replacing video platforms.[1][2]
• Scalability and Integrations: Cloud storage for tracking/sharing, EMR integration, life sciences tools for annotated datasets and novel biomarkers, serving providers, health systems, and bioPharma.[2][5]
• Global Reach and Ecosystem: Deployed in 800+ US hospitals, UK via CORE 500 launch with Imperial College London, and consumer options like Eko+ membership.[1][4]

Role in the Broader Tech Landscape

Eko Health rides the wave of AI-driven telehealth and remote patient monitoring, capitalizing on post-pandemic demand for virtual care that matches in-person diagnostic quality amid clinician shortages and rising cardiopulmonary disease burdens (e.g., structural heart disease, pulmonary hypertension).[1][2] Timing is ideal as digital health matures—FDA clearances and 600,000+ users reflect market forces like EHR integrations, bioPharma needs for real-world data, and underdiagnosed conditions driving early intervention.[2][6] Eko influences the ecosystem by creating the world's largest connected stethoscope network, enabling scaled AI training, partnerships (e.g., Mayo, Imperial), and hybrid care models that reduce in-person visits while boosting accuracy, positioning it as a foundational tool in cardiology evolution.[1][4][7]

Quick Take & Future Outlook

Eko Health is poised to dominate AI cardiopulmonary detection with expansions into new algorithms (pulmonary hypertension, respiratory disease), deeper bioPharma collaborations for digital biomarkers, and global scaling beyond UK/US.[2][4] Trends like hospital-at-home proliferation, AI regulatory tailwinds, and demand for remote physiological data will accelerate growth, potentially evolving Eko into a full-stack virtual exam platform influencing how 800M+ annual cardiac exams worldwide incorporate AI.[1][2] As the largest device network fuels richer datasets, Eko could redefine early disease detection, delivering the high-fidelity auscultation that powers next-gen care from clinic to anywhere.[1][5]